Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of...
51 insider purchases on record · latest filing 2024-09-16.
Insiders have also filed 330 sale transactions at LQDA.